SPEX - Spherix Incorporated

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.8600
+0.0100 (+1.18%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close0.8500
Open0.8800
Bid0.0000 x 4000
Ask0.0000 x 1800
Day's Range0.8500 - 0.8900
52 Week Range0.5500 - 1.5500
Volume48,174
Avg. Volume45,928
Market Cap7.347M
Beta (3Y Monthly)1.63
PE Ratio (TTM)4.10
EPS (TTM)0.2100
Earnings DateMay 13, 2019 - May 17, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1980-05-12
1y Target Est19.00
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    SmallCap Sentinel: A Gain of Uncommon Proportions

    ORLANDO, FL / ACCESSWIRE / March 13, 2019 / In the world of smaller equities, revenue, especially for emerging biotech or tech companies, can be fleeting, rare even. As such, Spherix Incorporated (SPEX) posting a one-time gain of $7.5 million in its 10-K should turn a few heads. It is notable that the $7.5 million one-time gain comes from an investment the Company and Spherex CEO Anthony Hayes made two years ago, putting $670k into a then private biotech called Hoth Therapeutics where Hayes saw potential and promise.

  • Spherix Announces Filing of its Annual Report on Form 10-K, Records $7.5 Million One Time Gain
    PR Newswire10 days ago

    Spherix Announces Filing of its Annual Report on Form 10-K, Records $7.5 Million One Time Gain

    NEW YORK , March 12, 2019 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX)- a technology development company committed to the fostering of innovative ideas, announced today that it has filed its Annual ...

  • 4 Stocks Join Ben Graham Net-Net Screener Friday
    GuruFocus.com14 days ago

    4 Stocks Join Ben Graham Net-Net Screener Friday

    While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active

  • Spherix Announces Preclinical Pancreatic Cancer Treatment Study Moving Forward
    PR Newswire4 months ago

    Spherix Announces Preclinical Pancreatic Cancer Treatment Study Moving Forward

    NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA).  PDA is considered the deadliest of major cancers and patients are in desperate need of improved therapies. PDA is caused by chronic inflammatory stress associated with the increasingly common afflictions of obesity, type 2 diabetes, and pancreatitis, exacerbated by smoking and drinking.  KPC34 is a candidate therapeutic because it is activated preferentially inside tumor cells to release an inhibitor of DNA replication and a separate tumor promotion inhibitor. Annually, more than 350,000 new cases of pancreatic cancer are diagnosed across the world.  According to the American Society of Clinical Oncology, a six-month course of gemcitabine, the chemotherapy drug typically used to treat advanced pancreatic cancer, costs about $23,500.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Twilio and Spherix

    NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Twilio shares were on the rise on an “outperform” rating reiterated from an Oppenheimer analyst last week while Spherix Incorporated shares popped on news ...

  • Spherix Announces Ownership Interest in Electric Scooter Business
    PR Newswire4 months ago

    Spherix Announces Ownership Interest in Electric Scooter Business

    From renting out an unused road bike, to running a fleet of hundreds of electric scooters, Mellow provides a flexible entry for anyone interested in the growing shared vehicles space. Additional information about the investment will be available in the Form 8-K, filed by Spherix with the Securities and Exchange Commission.

  • Spherix Announces the Addition of Dr. Rana Quraishi to Company's Advisory Board
    PR Newswire5 months ago

    Spherix Announces the Addition of Dr. Rana Quraishi to Company's Advisory Board

    NEW YORK, Oct. 29, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area. Dr. Rana Quraishi is the Director of New Ventures, at UM Ventures University of Maryland, Baltimore.  UM Ventures is a joint initiative bringing the University of Maryland, Baltimore and University of Maryland, College Park together to commercialize discoveries and create economic impact by engaging partners in industry and social ventures.  Dr. Quraishi has a Ph.D. in Molecular Biology and Biochemistry from Columbia University where she was also an undergraduate and an M.S. from Harvard University.

  • Newsfile5 months ago

    StockLab Reports: Of Mice and Men

    Las Vegas, Nevada--(Newsfile Corp. - October 25, 2018) - Early stage biotechnology and pharmaceutical companies often present a quandary for investors. The technology is generally difficult to understand and investors just can't fully picture the potential.Except when that picture is an absolutely stunning, must-see video from Wake Forest University of a mouse paralyzed by Acute Lymphoblastic Leukemia restored to mobility in two days by a drug now headed to the patent portfolio of ...

  • Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study
    PR Newswire5 months ago

    Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study

    Anthony Hayes, CEO of Spherix, stated, "This remarkable video demonstrates the tremendous potential for this drug to treat ALL.  The video was part of a written submission on KPC34 to PLOS OneTM a peer reviewed medical journal.

  • Spherix to Merge with CBM BioPharma Pharmaceutical Company
    PR Newswire5 months ago

    Spherix to Merge with CBM BioPharma Pharmaceutical Company

    NEW YORK, Oct. 11, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has entered into a merger agreement with CBM BioPharma, Inc. ("CBM") that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion dollar oncology therapeutics market. CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.

  • Spherix Announces Strategic Equity Investment in DatChat in Lieu of Full Company Merger
    PR Newswire7 months ago

    Spherix Announces Strategic Equity Investment in DatChat in Lieu of Full Company Merger

    NEW YORK, Aug. 15, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced it has terminated its merger agreement with DatChat. After strategic meetings with DatChat, both organziations believe there is a more effective strategy that will have the best opportunity for long-term growth. The Spherix Board of Directors determined that a strategic equity investment in DatChat will provide a better strategy for shareholders and allow Spherix to benefit from DatChat's platform and projected growth.

  • ACCESSWIRE9 months ago

    Free Pre-Market Technical Recap on Moody's and Three Additional Business Services Stocks

    Stock Research Monitor: ONE, SPEX, and TISI LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on MCO sign up now at www.wallstequities.com/registration . WallStEquities.com has ...

  • How Spherix Incorporated (NASDAQ:SPEX) Can Impact Your Portfolio Volatility
    Simply Wall St.9 months ago

    How Spherix Incorporated (NASDAQ:SPEX) Can Impact Your Portfolio Volatility

    For Spherix Incorporated’s (NASDAQ:SPEX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. SPEX is exposed toRead More...

  • Breaking Down Spherix Incorporated’s (NASDAQ:SPEX) Ownership Structure
    Simply Wall St.10 months ago

    Breaking Down Spherix Incorporated’s (NASDAQ:SPEX) Ownership Structure

    In this article, I’m going to take a look at Spherix Incorporated’s (NASDAQ:SPEX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • Spherix and DatChat Announce New User Interface and New Features for DatChat App
    PR Newswire10 months ago

    Spherix and DatChat Announce New User Interface and New Features for DatChat App

    Spherix and DatChat have been working together to enhance the user experience.  The result is Advanced Screenshot Protection that prevents the recipients of your messages and images from being able to take screenshots.  If a recipient tries to take a screenshot of a message or image sent from a DatChat user, the recipient will now only capture a blank screen and the sender will be notified that a screenshot was attempted. Additionally, the advanced screenshot prevention protects against other forms of screen capture, including iOS screen recording, AirPlay screen mirroring and QuickTime screen recording.

  • Is Spherix Incorporated (NASDAQ:SPEX) A Financially Sound Company?
    Simply Wall St.10 months ago

    Is Spherix Incorporated (NASDAQ:SPEX) A Financially Sound Company?

    While small-cap stocks, such as Spherix Incorporated (NASDAQ:SPEX) with its market cap of US$9.13M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • Spherix CEO, Anthony Hayes, Set to Appear Live on Cheddar TV Interview to Take Place From the Floor of the NYSE on May 9th 12:50 p.m.
    PR Newswire10 months ago

    Spherix CEO, Anthony Hayes, Set to Appear Live on Cheddar TV Interview to Take Place From the Floor of the NYSE on May 9th 12:50 p.m.

    Hayes to Discuss the Company's Recent Transformational Acquisition of DatChat NEW YORK , May 8, 2018 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX), a technology company committed to advancing innovation ...

  • Spherix Announces Adjustment to DatChat Acquisition Consideration
    PR Newswire10 months ago

    Spherix Announces Adjustment to DatChat Acquisition Consideration

    - Company to issue 11.5m fewer shares than initially contemplated - Effective Purchase Price Reduction of $15m - Renowned Cyber-Security Veteran Gregg Blattner to join the Board of Directors NEW YORK , ...

  • Spherix Highlights Size of Multi-Billion Dollar Mobile Messaging Sector
    PR Newswire11 months ago

    Spherix Highlights Size of Multi-Billion Dollar Mobile Messaging Sector

    Company Details New Opportunities Following DatChat Acquisition NEW YORK , April 11, 2018 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) a technology company committed to advancing innovation by participation ...

  • Spherix Issues Letter to Shareholders
    PR Newswirelast year

    Spherix Issues Letter to Shareholders

    One of the driving forces of our Company is our pursuit of business strategies and investments that stand to benefit from both the rapid pace of technological change and ever changing complexities of consumer behavior. Spherix's proposed merger with DatChat provides a working solution to the growing privacy problem.

  • Spherix Expands Blockchain Investment
    PR Newswirelast year

    Spherix Expands Blockchain Investment

    NEW YORK, March 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) announced today that the Company has closed an investment in TheBit Daily LLC ("TheBit"), a development stage media and education platform focused on the blockchain and cryptocurrency space.  The site provides strategic and intelligently condensed insight to this exciting technology.  For more information, please visit: www.thebitdaily.com. TheBit Daily aims to lower the barrier of entry into the blockchain and cryptocurrency technology fields.  TheBit informs readers, who range from beginners to experts, through its easy to understand "Guides" on the main concepts behind blockchain and cryptocurrencies.  TheBit offers a free custom-curated newsletter that apprises users on the latest updates and events impacting the blockchain and cryptocurrencies sectors.

  • With A -118.45% Earnings Drop, Is Spherix Incorporated’s (NASDAQ:SPEX) A Concern?
    Simply Wall St.last year

    With A -118.45% Earnings Drop, Is Spherix Incorporated’s (NASDAQ:SPEX) A Concern?

    Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Spherix Incorporated’s (NASDAQ:SPEX) track record on a highRead More...